Mawson Infrastructure Group a clinical-stage biopharmaceutical company focused on the treatment of ophthalmic disorders, including dry eye syndrome (DES). Co. has in-licensed certain rights to purchase, market, sell and distribute a formula known as LO2A, a drug developed for the treatment of DES, and other ophthalmological illnesses, including Conjunctivochalasis (CCH) and Sjogren's syndrome (Sjogren's). LO2A is registered and marketed by its inventor in Germany and Switzerland for the treatment of DES, in Hungary for the treatment of DES, CCH and ophthalmological symptoms of Sjogren's and in the Netherlands for the treatment of DES and protection from dry eye as a result of Sjogren's. The MIGI stock yearly return is shown above.
The yearly return on the MIGI stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2018 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the MIGI annual return calculation with any dividends reinvested as applicable (on ex-dates).
|